Risankizumab-rzaa

Risankizumab, sold under the brand name Skyrizi, is a humanized monoclonal antibody targeting interleukin 23A (IL-23A).[5] Risankizumab is part of a collaboration between Boehringer Ingelheim and AbbVie. Risankizumab has been approved in the European Union,[4] the United States,[3][6] and Canada[7] for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. In Japan,... [wikipedia]